Abstract 2044P
Background
BSI are a frequent and severe complication in cancer. Recent changes in oncological treatment, supportive care and development of new antimicrobial therapies could have affected its epidemiology, management and outcomes. Our aim is to describe clinical and microbiological features, antibiotic therapy, outcomes and mortality-related risk factors of BSI in cancer patients.
Methods
We performed a retrospective, observational, unicentric study. Microbiologically-confirmed BSI episodes in cancer patients between January 2017 and December 2021 were collected. We analysed clinical and microbiological data, empirical antibiotic treatment (EAT) and outcomes. A binary logistic regression model was used to detect variables related to 7 and 30-days mortality. P values <0.05 were considered significant.
Results
438 episodes of BSI were documented in 362 patients. Most frequent neoplasms were pancreatobiliary (25.1%), colorectal (16.9%), lung (11.9%) and breast (9.1%) tumours. 78.1% were metastatic. 72.1% had received chemotherapy in the previous month. The most common sources of BSI were vascular catheters (26.9%), cholangitis (23.1%) and other abdominal infections (22.8%). Gram-negative bacteria (GNB) were isolated in 60.3% of cases and Gram-positive bacteria in 45.4%. Yeasts were isolated in 3.9% of cases. Most common organisms were E. coli (29.7%), Klebsiella spp. (15.1%), coagulase-negative staphylococcus (12.6%) and S. aureus (10.3%). Most used EAT was piperacillin/tazobactam (43.2%), followed by meropenem (18.3%), amoxicilin/clavulanic acid (16%) and vancomycin (14.8%). Adequate EAT was given to 76.3% of patients. Mortality at 7 and 30 days was 11.2% and 24.4%, respectively. Statistical analysis showed lung cancer, respiratory source, yeasts and Pseudomonas spp. as independent risk factors for 7 and 20-days mortality.
Conclusions
BSI is a severe complication associated to elevated mortality in cancer patients. Most frequent sources of BSI are vascular catheters, cholangitis and abdominal infections. Most of them occur in patients with metastatic digestive tumours and are caused by GNB. Lung cancer, respiratory infections, isolation of yeasts and Pseudomonas spp. could imply a worse prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06